Physician profile
David A Deems
NPI 1346216850
$6,855.40
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,613 · 2020: $569 · 2021: $1,866 · 2022: $1,980 · 2023: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $757.18 | 2019-2023 | Ubrelvy, Vraylar |
| Lilly USA, LLC | $741.80 | 2019-2023 | Jardiance, Mounjaro, Emgality |
| Astrazeneca Pharmaceuticals LP | $730.43 | 2019-2023 | Farxiga, Breztri |
| Novo Nordisk INC | $604.75 | 2019-2023 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $591.37 | 2019-2023 | Shingrix, Trelegy Ellipta |
| Amarin Pharma, INC. | $307.51 | 2019-2022 | |
| Amgen INC. | $282.09 | 2019-2023 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $280.07 | 2019-2022 | |
| Allergan, INC. | $235.91 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.15 | 2019-2023 | Tradjenta, Synjardy, Glyxambi |
| Pfizer INC. | $181.90 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $137.87 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $137.15 | 2020-2021 | |
| Abbott Laboratories | $133.04 | 2019-2022 | |
| Dexcom, INC. | $132.18 | 2021-2023 | Dexcom G6 Transmitter |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Deems listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.